Chromocell Therapeutics(CHRO) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1 million in net revenues 2,716 ZELSUVMI units prescribed by 1,169 unique prescribers in the third quarter of fiscal 2025 DURHAM, N.C., November 13, 2025 — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical comp ...